Spiro-lactam nmda receptor modulators and uses thereof

Abstract

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

1 .- 4 . (canceled) 
     
     
         5 . A compound represented by formula I: 
       
         
           
           
               
               
           
         
       
       or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
 R b  is H; 
 R 1  is H; 
 R 2  is H; 
 R 3  is —C(O)R 32 , wherein R 32  is —CH 3 ; 
 R 5  has the formula —CH(CHR 4 R 6 )—X, wherein X is 1,3,4-oxadiazolyl; 
 R 4  is methyl; and 
 R 6  is hydroxyl. 
 
     
     
         6 . A pharmaceutical composition, the pharmaceutical composition comprising:
 a compound represented by formula I:   
       
         
           
           
               
               
           
         
       
       or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
 R b  is H; 
 R 1  is H; 
 R 2  is H; 
 R 3  is —C(O)R 32 , wherein R 32  is —CH 3 ; 
 R 5  has the formula —CH(CHR 4 R 6 )—X, wherein X is 1,3,4-oxadiazolyl; 
 R 4  is methyl; and 
 R 6  is hydroxyl; and 
 a pharmaceutically acceptable excipient.